TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET 38
1.4 LIMITATIONS 40
1.5 MARKETS COVERED 40
2 MARKET SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 CURRENCY AND PRICING 45
2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
2.6 MULTIVARIATE MODELLING 49
2.7 PRODUCT SEGMENT LIFELINE CURVE 49
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.9 DBMR MARKET POSITION GRID 51
2.10 MARKET APPLICATION COVERAGE GRID 52
2.11 VENDOR SHARE ANALYSIS 53
2.12 SECONDARY SOURCES 54
2.13 ASSUMPTIONS 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 58
4.1 PORTERS FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
5 MARKET OVERVIEW 61
5.1 DRIVERS 63
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 63
5.1.2 INCREASING APPLICATION OF CYTOMETRY INSTRUMENTS 64
5.1.3 INCREASE IN USE OF FLOW CYTOMETRY IN DRUG DISCOVERY 65
5.1.4 GROWTH IN STEM CELL RESEARCH AND ACQUISITION OF RECOMBINATION OF DNA TECHNOLOGIES 67
5.2 RESTRAINTS 68
5.2.1 HIGH COST OF FLOW CYTOMETRY INSTRUMENTS 68
5.2.2 LIMITATIONS OF FLOW CYTOMETRY 69
5.2.3 LACK OF SKILLED PROFESSIONALS 70
5.3 OPPORTUNITIES 71
5.3.1 INCREASE IN ADOPTION OF FLOW CYTOMETRY TECHNIQUES IN RESEARCH AND ACADEMIA 71
5.3.2 DEVELOPMENT IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 72
5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 73
5.3.4 DEVELOPING A PIPELINE OF STEM CELL RESEARCH 74
5.4 CHALLENGES 74
5.4.1 DIFFICULTY IN THE DEVELOPMENT AND VALIDATION OF FLOW CYTOMETRY ASSAYS 74
5.4.2 COMPLEXITIES RELATED TO REAGENT DEVELOPMENT 75
6 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY PRODUCT 77
6.1 OVERVIEW 78
6.2 REAGENTS AND CONSUMABLES 81
6.2.1 DYE 82
6.2.2 ANTIBODIES 82
6.2.3 BEADS 82
6.2.4 OTHERS 82
6.3 FLOW CYTOMETRY INSTRUMENTS 82
6.3.1 CELL ANALYZERS 83
6.3.1.1 CELL ANALYZERS, BY TYPE 84
6.3.1.1.1 IMAGING FLOW CYTOMETERS 84
6.3.1.1.2 NON-IMAGING FLOW CYTOMETERS 84
6.3.1.2 CELL ANALYZERS, BY MODALITY 84
6.3.1.2.1 BENCHTOP 84
6.3.1.2.2 STANDALONE 84
6.3.2 CELL SORTERS 85
6.3.2.1 BENCHTOP 85
6.3.2.2 STANDALONE 85
6.4 ACCESSORIES 85
6.4.1 FILTERS 86
6.4.2 DETECTORS 86
6.4.3 OTHERS 86
6.5 SERVICES 87
6.6 SOFTWARE 87
7 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY TECHNOLOGY 89
7.1 OVERVIEW 90
7.2 CELL-BASED FLOW CYTOMETRY 94
7.3 BEAD-BASED FLOW CYTOMETRY 95
8 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY APPLICATION 96
8.1 OVERVIEW 97
8.2 RESEARCH APPLICATIONS 101
8.2.1 CELL CYCLE ANALYSIS 102
8.2.2 CELL SORTING/SCREENING 102
8.2.3 CELL TRANSFECTION/VIABILITY 102
8.2.4 PHARMACEUTICAL AND BIOTECHNOLOGY 103
8.2.4.1 DRUG DISCOVERY 103
8.2.4.2 STEM CELL RESEARCH 103
8.2.4.3 IN VITRO TOXICITY TESTING 103
8.2.5 IMMUNOLOGY 103
8.2.6 APOPTOSIS 103
8.2.7 CELL COUNTING 103
8.2.8 OTHERS 103
8.3 CLINICAL APPLICATIONS 104
8.3.1 HAEMATOLOGY 105
8.3.2 CANCER 105
8.3.3 IMMUNODEFICIENCY DISEASES 105
8.3.4 ORGAN TRANSPLANTATION 105
8.3.5 OTHER CLINICAL APPLICATION 105
8.4 INDUSTRIAL APPLICATIONS 105
9 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY END USER 107
9.1 OVERVIEW 108
9.2 PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES 111
9.3 ACADEMIC & RESEARCH INSTITUTES 112
9.4 HOSPITALS 113
9.5 CLINICAL TESTING LABORATORIES 114
9.6 BLOOD BANK 115
9.7 OTHERS 116
10 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY DISTRIBUTION CHANNEL 117
10.1 OVERVIEW 118
10.2 RETAIL SALES 121
10.3 DIRECT TENDERS 122
11 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, BY GEOGRAPHY 123
11.1 MIDDLE EAST AND AFRICA 124
11.1.1 SOUTH AFRICA 132
11.1.2 SAUDI ARABIA 136
11.1.3 U.A.E 140
11.1.4 EGYPT 144
11.1.5 REST OF MIDDLE EAST AND ARICA 148
12 MIDDLE EAST & AFRICA FLOW CYTOMETRY MARKET, COMPANY LANDSCAPE 149
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 149
13 SWOT ANALYSIS 150
14 COMPANY PROFILE 151
14.1 THERMO FISHER SCIENTIFIC INC. 151
14.1.1 COMPANY SNAPSHOT 151
14.1.2 REVENUE ANALYSIS 152
14.1.3 COMPANY SHARE ANALYSIS 152
14.1.4 PRODUCT PORTFOLIO 153
14.1.5 RECENT DEVELOPMENTS 153
14.2 BD 155
14.2.1 COMPANY SNAPSHOT 155
14.2.2 REVENUE ANALYSIS 155
14.2.3 COMPANY SHARE ANALYSIS 156
14.2.4 PRODUCT PORTFOLIO 156
14.2.5 RECENT DEVELOPMENT 157
14.2.5.1 COLLABORATION 157
14.3 AGILENT TECHNOLOGIES, INC. 158
14.3.1 COMPANY SNAPSHOT 158
14.3.2 REVENUE ANALYSIS 158
14.3.3 COMPANY SHARE ANALYSIS 159
14.3.4 PRODUCT PORTFOLIO 159
14.3.5 RECENT DEVELOPMENTS 160
14.4 SARTORIUS AG 161
14.4.1 COMPANY SNAPSHOT 161
14.4.2 REVENUE ANALYSIS 161
14.4.3 COMPANY SHARE ANALYSIS 162
14.4.4 PRODUCT PORTFOLIO 162
14.4.5 RECENT DEVELOPMENT 163
14.5 NEXCELOM BIOSCIENCE LLC 164
14.5.1 COMPANY SNAPSHOT 164
14.5.2 PRODUCT PORTFOLIO 164
14.5.3 RECENT DEVELOPMENT 164
14.5.4 COMPANY SHARE ANALYSIS 165
14.6 APOGEE FLOW SYSTEMS LTD. 166
14.6.1 COMPANY SNAPSHOT 166
14.6.2 PRODUCT PORTFOLIO 166
14.6.3 RECENT DEVELOPMENT 166
14.7 BAY BIOSCIENCE CO., LTD. 167
14.7.1 COMPANY SNAPSHOT 167
14.7.2 PRODUCT PORTFOLIO 167
14.7.3 RECENT DEVELOPMENT 167
14.8 BIOMRIEUX 168
14.8.1 COMPANY SNAPSHOT 168
14.8.2 REVENUE ANALYSIS 169
14.8.3 PRODUCT PORTFOLIO 169
14.8.4 RECENT DEVELOPMENT 169
14.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 170
14.9.1 COMPANY SNAPSHOT 170
14.9.2 REVENUE ANALYSIS 170
14.9.3 PRODUCT PORTFOLIO 171
14.9.4 RECENT DEVELOPMENTS 172
14.9.4.1 ACQUISITION 172
14.9.4.2 PRODUCT LAUNCH 172
14.10 BENNUBIO INC. 174
14.10.1 COMPANY SNAPSHOT 174
14.10.2 PRODUCT PORTFOLIO 174
14.10.3 RECENT DEVELOPMENT 174
14.11 BIOLEGEND, INC. 175
14.11.1 COMPANY SNAPSHOT 175
14.11.2 PRODUCT PORTFOLIO 175
14.11.3 RECENT DEVELOPMENT 177
14.12 BIO-RAD LABORATORIES, INC. 178
14.12.1 COMPANY SNAPSHOT 178
14.12.2 REVENUE ANALYSIS 178
14.12.3 PRODUCT PORTFOLIO 179
14.12.4 RECENT DEVELOPMENT 179
14.13 CELL SIGNALING TECHNOLOGY, INC. 180
14.13.1 COMPANY SNAPSHOT 180
14.13.2 PRODUCT PORTFOLIO 180
14.13.3 RECENT DEVELOPMENT 181
14.14 CELLKRAFT BIOTECH PVT. LTD 182
14.14.1 COMPANY SNAPSHOT 182
14.14.2 PRODUCT PORTFOLIO 182
14.14.3 RECENT DEVELOPMENT 183
14.15 CYTEK BIOSCIENCES 184
14.15.1 COMPANY SNAPSHOT 184
14.15.2 PRODUCT PORTFOLIO 184
14.15.3 RECENT DEVELOPMENTS 185
14.15.3.1 PRODUCT LAUNCH 185
14.15.3.2 ACQUISITION 186
14.16 CYTOBUOY B.V. 187
14.16.1 COMPANY SNAPSHOT 187
14.16.2 PRODUCT PORTFOLIO 187
14.16.3 RECENT DEVELOPMENT 187
14.17 CYTONOME/ST, LLC 188
14.17.1 COMPANY SNAPSHOT 188
14.17.2 PRODUCT PORTFOLIO 188
14.18 COHERENT CORP. 189
14.18.1 COMPANY SNAPSHOT 189
14.18.2 REVENUE ANALYSIS 189
14.18.3 PRODUCT PORTFOLIO 190
14.18.4 RECENT DEVELOPMENTS 190
14.18.4.1 Announcement 190
14.18.4.2 PRODUCT LAUNCH 190
14.18.4.3 AWARDS 191
14.18.5 RECENT DEVELOPMENT 191
14.19 ELABSCIENCE BIOTECHNOLOGY INC. 192
14.19.1 COMPANY SNAPSHOT 192
14.19.2 PRODUCT PORTFOLIO 192
14.19.3 RECENT DEVELOPMENT 193
14.20 ENZO BIOCHEM INC. 194
14.20.1 COMPANY SNAPSHOT 194
14.20.2 REVENUE ANALYSIS 195
14.20.3 PRODUCT PORTFOLIO 195
14.20.4 RECENT DEVELOPMENT 195
14.21 IKEDA SCIENTIFIC CO., LTD. 196
14.21.1 COMPANY SNAPSHOT 196
14.21.2 PRODUCT PORTFOLIO 196
14.21.3 RECENT DEVELOPMENT 197
14.22 MERCK KGAA 198
14.22.1 COMPANY SNAPSHOT 198
14.22.2 REVENUE ANALYSIS 198
14.22.3 PRODUCT PORTFOLIO 199
14.22.4 RECENT DEVELOPMENT 199
14.23 MILTENYI BIOTEC 200
14.23.1 COMPANY SNAPSHOT 200
14.23.2 PRODUCT PORTFOLIO 200
14.23.3 RECENT DEVELOPMENT 202
14.23.3.1 PRODUCT LAUNCH 202
14.24 NANOCELLECT BIOMEDICAL 203
14.24.1 COMPANY SNAPSHOT 203
14.24.2 PRODUCT PORTFOLIO 203
14.24.3 RECENT DEVELOPMENTS 203
14.25 NEOGENOMICS LABORATORIES 205
14.25.1 COMPANY SNAPSHOT 205
14.25.2 REVENUE ANALYSIS 205
14.25.3 PRODUCT PORTFOLIO 206
14.25.4 RECENT DEVELOPMENT 206
14.26 ON-CHIP BIOTECHNOLOGIES CO., LTD. CORPORATION 207
14.26.1 COMPANY SNAPSHOT 207
14.26.2 PRODUCT PORTFOLIO 207
14.26.3 RECENT DEVELOPMENTS 207
14.27 ORFLO TECHNOLOGIES 208
14.27.1 COMPANY SNAPSHOT 208
14.27.2 PRODUCT PORTFOLIO 208
14.27.3 RECENT DEVELOPMENT 208
14.28 Q2 SOLUTION 209
14.28.1 COMPANY SNAPSHOT 209
14.28.2 REVENUE ANALYSIS 209
14.28.3 SERVICE PORTFOLIO 210
14.28.4 RECENT DEVELOPMENT 210

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.